Search Results for: -e9g30cr.html

DRS. ROGER B. COHEN, LEE M. ELLIS AND JOHN L. MARSHALL JOIN ACTUATE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD

CHICAGO, IL and FORT WORTH, TX, October 18, 2022 – Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced the addition of eminent cancer research leaders Roger B. Cohen, MD, Lee M. Ellis, MD, and John L. Marshall, MD to their Scientific Advisory Board.  Dr. Roger […]

DRS. ROGER B. COHEN, LEE M. ELLIS AND JOHN L. MARSHALL JOIN ACTUATE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD Read More »

2022-ASCO-Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/ irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.

2022-ASCO-Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/ irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results. Read More »